Dr Yelena Janjigian talks to ecancer about the MATTERHORN study, which she presented at ASCO 2025.

This looked at adding durvalumab to the FLOT chemotherapy regimen before and after surgery, with follow-up treatment with durvalumab only, improved outcomes for patients with stage II, III, or IVA untreated, resectable gastric cancer (GC) and gastroesophageal junction cancer (GEJC) 

There was a statistically significant improvement in event-free survival (EFS) between the durvalumab with FLOT arm compared to the placebo with FLOT arm.

Click here to read the news story with the latest data